Breast cancer chemoprevention: is tamoxifen a rational choice?

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.

Gynecologic oncology·2024

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

British journal of cancer·2023

Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies.

Translational oncology·2018

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

'Life has become a lot easier'-the acceptability of the treatable traits clinic experience to people with bronchiectasis.

Annals of medicine·2026

Patient-Reported Outcome scale for Bronchiectasis (BE-PRO): development and validation in China.

Annals of medicine·2026

Responsiveness and minimal important change of Turkish pain-related psychological measures in chronic non-specific low back pain.

Annals of medicine·2026

Perceived barriers to eye care use among secondary school students with pinhole-improvable reduced visual acuity in two schools in Kampala, Uganda: a cross-sectional study.

Annals of medicine·2026

Differential diagnostic value of PAX1 and JAM3 methylation for cervical intraepithelial neoplasia between premenopausal and postmenopausal women: a retrospective clinical study in China.

Annals of medicine·2026

Dual-targeted nanotechnology for gynaecological cancers: a comprehensive review of mechanisms and clinical potential.

Annals of medicine·2026

Cannabidiol/cannabigerol exposure and neuropathy-related outcomes after neurotoxic chemotherapy: a real-world cohort study.

Frontiers in pain research (Lausanne, Switzerland)·2026

Clinical characteristics and immunotherapy in Chinese patients with Merkel cell carcinoma: a retrospective analysis.

Frontiers in oncology·2026

Randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder.

BMJ mental health·2026

Safety evaluation of sub-chronic oral exposure to ochratoxin A and citrinin in Wistar rats.

Regulatory toxicology and pharmacology : RTP·2026

Ameliorative character of eugenol and propargylated eugenol against letrozole induced polycystic ovarian syndrome in in-vivo zebrafish model.

Tissue & cell·2026

Dose-Dependent Effects, Metabolic Paradoxes, and Nutritional Implications of Flavonoids and Cancer.

Nutrition reviews·2026

Related Experiment Videos

Breast cancer chemoprevention: is tamoxifen a rational choice?

Related Concept Videos

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.

'Life has become a lot easier'-the acceptability of the treatable traits clinic experience to people with bronchiectasis.

Patient-Reported Outcome scale for Bronchiectasis (BE-PRO): development and validation in China.

Responsiveness and minimal important change of Turkish pain-related psychological measures in chronic non-specific low back pain.

Perceived barriers to eye care use among secondary school students with pinhole-improvable reduced visual acuity in two schools in Kampala, Uganda: a cross-sectional study.

Differential diagnostic value of PAX1 and JAM3 methylation for cervical intraepithelial neoplasia between premenopausal and postmenopausal women: a retrospective clinical study in China.

Dual-targeted nanotechnology for gynaecological cancers: a comprehensive review of mechanisms and clinical potential.

Cannabidiol/cannabigerol exposure and neuropathy-related outcomes after neurotoxic chemotherapy: a real-world cohort study.

Clinical characteristics and immunotherapy in Chinese patients with Merkel cell carcinoma: a retrospective analysis.

Randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder.

Safety evaluation of sub-chronic oral exposure to ochratoxin A and citrinin in Wistar rats.

Ameliorative character of eugenol and propargylated eugenol against letrozole induced polycystic ovarian syndrome in in-vivo zebrafish model.

Dose-Dependent Effects, Metabolic Paradoxes, and Nutritional Implications of Flavonoids and Cancer.

Related Experiment Videos

Breast cancer chemoprevention: is tamoxifen a rational choice?

Related Concept Videos

Related Articles